Apexigen

Apexigen announces Clinical Collaboration on a New Phase 2 Trial for APX005M in Sarcoma

Apexigen today announced a collaboration with Columbia University Irving Medical Center on a new Phase 2 study for its lead immuno-oncology (I-O) therapeutic APX005M, a monoclonal antibody targeting CD40, in combination with doxorubicin and olaratumab in patients with advanced sarcomas. The trial is being funded by Apexigen and is being conducted by researchers at Columbia[…]

Apexigen

Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy

San Carlos, CA, and New Haven, CT – June 14, 2018 Apexigen and Yale Cancer Center today announced a clinical trial collaboration to evaluate Apexigen’s APX005M in combination with cabiralizumab and Opdivo in patients with advanced solid tumors. The Phase 1/2 clinical trial will evaluate the safety, tolerability, and preliminary activity of APX005M in combination with cabiralizumab[…]

Apexigen

Apexigen Announces New Collaboration with UCSF

Apexigen today announced the initiation of patient enrollment in Phase 2 clinical trial in collaboration with the University of California San Francisco (UCSF). This trial is designed to evaluate Apexigen’s CD40 agonistic antibody, APX005M, in combination with multimodal treatment (chemotherapy and radiation therapy) in patients with resectable esophageal and gastroesophageal junction cancers.

Apexigen

Apexigen Receives Clinical Development Milestone Payment under Collaboration Agreement

Apexigen, Inc., — a clinical-stage biopharmaceutical company focusing on discovering and developing antibody-based therapeutics for the treatment of cancer with an emphasis on new Immuno-Oncology (I-O) agents, today announced the receipt of a milestone payment under a license agreement for its proprietary APXiMAB™ technology. The milestone payment was associated with the achievement of a clinical development[…]